The impact of thrombocytosis on clinicopathological prognostic factors and survival in patients with vulvar cancer

Basit Öğe Kaydı
dc.contributor.authorUysal, Ahmet
dc.contributor.authorGultekin, Emre
dc.contributor.authorTaner, Cuneyt Eftal
dc.contributor.authorMun, Semih
dc.contributor.authorYidirim, Yusuf
dc.date.accessioned2025-01-27T20:52:30Z
dc.date.available2025-01-27T20:52:30Z
dc.date.issued2013
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPurpose: Reactive thrombocytosis in many solid tumors has widely been studied. In the present study we aimed to investigate whether thrombocytosis is a common and prognostic factor in women with vulvar cancer. Material & Methods: The preoperative platelet counts of 41 women, treated for vulvar cancer in our onco-gynecology center between March 1994 and January 2007, were retrospectively reviewed and correlated to clinical and pathological prognostic factors and 5-year survival. The chi-square or Fisher exact tests were used to compare categorical variables. P value <0.05 was accepted for statistical significance. Results: The mean age was 65.4+/-11.3 years (range 39-83y). All patients had squamous histology. The mean platelet count was 335.42x109/L +/- 82.03 (range 142-1155x109/L). Thrombocytosis was detected in 8 (19.5%) patients. No correlation was found between thrombocytosis and grade (p=0.65), LVSI (p=0.82), tumor size (p=0.73), depth of invasion (p=0.18), lymph node metastasis (0.93), and FIGO stage (p=0.78). The mean follow up time was 118.0+/-43.1 months (range 60-213 months). At the end of the study period 14 patients (34.2%) had died, 8 (19.5%) had recurrence, 19 (46.3%) were disease-free. General 5-year survival was 68.3% (28/41). The 5-year survival rate for patients with thrombocytosis was 75.0% (6/8), which was not significantly different from the 5-year survival of patients with normal platelet counts (22/33; 66.7%) (p=0.75). Conclusion: Our study showed that, overall, thrombocytosis was found in about 20% of patients with vulvar cancer and proved to be not linked to the best known prognostic factors and survival. Thus, disease stage and inguinofemoral lymph node status continue to be the best prognostic factors for this disease.
dc.identifier.endpage455
dc.identifier.issn0017-0011
dc.identifier.issn2543-6767
dc.identifier.issue6
dc.identifier.pmid24032263
dc.identifier.scopus2-s2.0-84881344471
dc.identifier.scopusqualityQ3
dc.identifier.startpage450
dc.identifier.urihttps://hdl.handle.net/20.500.12428/25779
dc.identifier.volume84
dc.identifier.wosWOS:000330996800007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherVia Medica
dc.relation.ispartofGinekologia Polska
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectthrombocytosis
dc.subjectvulvar cancer
dc.subjectprognostic factors
dc.subjectsurvival
dc.titleThe impact of thrombocytosis on clinicopathological prognostic factors and survival in patients with vulvar cancer
dc.title.alternativeWp?yw trombocytozy na prognostyczne czynniki kliniczno-patologiczne i prze?ycie pacjentek z rakiem sromu
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu